G894T NOS III GENE POLYMORPHISM AND RESISTANT HYPERTENSION IN THE UZBEK POPULATION
Abstract
The aim: to study the G894T gene polymorphism of the NOS3 gene on the risk of developing resistant arterial hypertension (AH) in Uzbek population.
Materials and Methods: The study included 176 patients with I-III degree of AH, who are on outpatient treatment at the Republican Specialized Scientific and Practical Medical Center of Cardiology. Genomic DNA was isolated from whole blood using the DiatomTM DNA Prep 200 kit (Laboratory IsoGen, Russia) according to the manufacturer's standard protocol. The quantity and quality of isolated DNA were assessed using gel electrophoresis and a NanoDrop spectrophotometer (Thermo Scientific, USA). Gene polymorphisms were identified by real-time polymerase chain reaction using allele and gene-specific primers and probes.Results: An analysis using genetic models of inheritance revealed an association of the C allele T704C of the AGT gene polymorphism with resistant hypertension and a protective effect of the G allele G894T of the NOS3 gene polymorphism on the risk of developing resistant hypertension in the Uzbek population.Conclusion: C allele and CC genotype T704C of the AGT gene polymorphism are associated with resistant hypertension. Carrying the G allele and GG genotype G894T of the NOS3 gene polymorphism is associated with a low risk of developing resistant hypertension in Uzbek population.
References
Owiredu, W.K.B.A.; Appiah, M.; Obirikorang, C.; Adu, E.A.; Boima, V.; Amos-Abanyie, E.K.; Akyaw, P.A.; Owiredu, E.-W.; Acheampong, E. Association of MYH9-rs3752462 polymorphisms with chronic kidney disease among clinically diagnosed hypertensive patients: A case-control study in a Ghanaian population. Clin. Hypertens. 2020, 26, 1–9.
Bloch, M.J. Worldwide prevalence of hypertension exceeds 1.3 billion. J. Am. Soc. Hypertens. 2016, 10, 753–754.
Sombié, H.K.; Kologo, J.K.; Tchelougou, D.; Ouédraogo, S.Y.; Ouattara, A.K.; Compaoré, T.R.; Nagalo, B.M.; Sorgho, A.P.; Nagabila, I.; Soubeïga, S.T.; et al. Positive association between ATP2B1 rs17249754 and essential hypertension: A case-control study in Burkina Faso, West Africa. BMC Cardiovasc. Disord. 2019, 19, 155.
Zhou, B.; Bentham, J.; Di Cesare, M.; Bixby, H.; Danaei, G.; Cowan, M.J.; Paciorek, C.J.; Singh, G.; Hajifathalian, K.; Bennett, J.E.; et al. Worldwide trends in blood pressure from 1975 to 2015: A pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet 2017, 389, 37–55.
Cheong, A.T.; Sazlina, S.G.; Tong, S.F.; Azah, A.S.; Salmiah, S. Poor blood pressure control and its associated factors among older people with hypertension: A cross-sectional study in six public primary care clinics in Malaysia. Malays. Fam. Phys. 2015, 10, 19–25.
Firmo, J.O.A.; Mambrini, J.V.d.M.; Peixoto, S.V.; Loyola Filho, A.I.d.; Souza Junior, P.R.B.d.; Andrade, F.B.d.; Lima-Costa, M.F. Adequate control of hypertension among older adults: ELSI-Brazil. Revista Saude Publica 2018, 52, 13s.
Pender, K.; Omole, O. Blood pressure control and burden of treatment in South African primary healthcare: A cross-sectional study. Afr. J. Prim. Health Care Fam. Med. 2019, 11, 7.
[Seedat, Y.; Rayner, B.; Veriava, Y. South African hypertension practice guideline 2014. Cardiovasc. J. Afr. 2014, 25, 288–294. [CrossRef] 9. Yaxley, J.P.; Thambar, S.V. Resistant hypertension: An approach to management in primary care. J. Fam. Med. Prim. Care 2015, 4, 193–199].
Kaplan N.M. Resistant hypertension// J.Hypertens. 2005. V. 23.P. 1441-1444
Persell S.D. Prevalence of resistant hypertension in the United States, 2003-2008 // Hypertension. 2011. V.57. P.1076-1080
Holecki M.,Dulawa J., Chulek J. Resistant hypertension in visceral obesity// Eur. J. Intern. Med. 2012. V. 23. P. 643-648
Bramalage P., Pittrow D., Witchen H.U. et.al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled // Am. J. Hypertens. 2004. V. 17. P. 904-910.
Jordan J., Yumuk V., Schlaich M. et al. Joint statement of the European association for the study of obesity and the European society of hypertension: obesity and difficult to treat arterial hypertension// J.Hypertens. 2012. V. 30. P. 1047-1055.
Engbaek M., Hjerrild M., Hallas J., Jacobsen I.A. The effect of low-dose spironolactone on resistance hypertension // J. Am. Soc. Hypertens. 2010. V. 4. 290-294.
Tsioufis C., Kordalis A., Flessas D. et al. Pathophysiology of resistance hypertension: the role of sympathetic nervous system // Int. J. Hypertens. 2011. doi: 10.4061/2011/642416.
Zatz R., Baylis C. Chronic nitric oxide inhibition model six years on // Hypertension. 1998. V. 32. P. 958-964.
Mabhida SE, Mashatola L, Kaur M, Sharma JR, Apalata T, Muhamed B, Benjeddou M Hypertension in African Populations: Review and Computational Insights., Johnson R.Genes (Basel). 2021 Apr 6;12(4):532.
Yasuo Takahashi1*, Keiko Yamazaki1,2, Yoichiro Kamatani3, Michiaki Kubo4,Koichi Matsuda5 & Satoshi Asai1,6.
Yugar-Toledo JC, Martin JF, Krieger JE, Pereira AC, Demacq C, Coelho OR, Pimenta E, Calhoun DA, Júnior HM. Gene variation in resistant hypertension: multilocus analysis of the angiotensin 1-converting enzyme, angiotensinogen, and endothelial nitric oxide synthase genes.DNA Cell Biol. 2011 Aug;30(8):555-64. doi: 10.1089/dna.2010.1156. Epub 2011 Mar 27.
Schunkert H, Hense HW, Döring A, Riegger GA, Siffert W. Association between a polymorphism in the G protein beta3 subunit gene and lower renin and elevated diastolic blood pressure levels. Hypertension. 1998;32(3):510–3.
